Diapositiva 1
![PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cad0421203b35bdec3bcffd87abb3ca1fd4c1ef4/3-Figure1-1.png "PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar")
PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
外科 - dose - dense - EC - 乳腺 - q2w
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
0226】dose-dence EC 療法(DDEC 療法)
Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial - Lambertini - 2020 - International Journal of Cancer -
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) - ScienceDirect
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial - The Lancet
![PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cad0421203b35bdec3bcffd87abb3ca1fd4c1ef4/6-Figure2-1.png "PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar")
PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial - ScienceDirect
Quoi de neuf en 2022 ? La chimiothérapie dose-dense en adjuvant dans les tumeurs RH+ (essai GIM2)
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial - The Lancet
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
dose-dense EC療法
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet
hematooncology.com . bis . Juni, Chicago
Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials | SpringerLink
Trial design of AGO trial, intense dose-dense epirubicin, paclitaxel,... | Download Scientific Diagram
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial - ScienceDirect
Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis - Xiu - 2022 -
